Description
Recently, the transdermal route has vied with oral treatment as the most successful innovative research area in API delivery. In the USA (the most important pharmaceutical market), out of 129 API delivery products under clinical evaluation, 51 are transdermal or dermal systems; 30% of 77 candidate products in preclinical development represent such API delivery. The worldwide transdermal patch market approaches $20 billion, yet is based on only 20 drugs. This rather limited number of drug substances is attributed to the excellent barrier function of the skin, which is accomplished almost entirely by the outermost 10–15 μm (in the dry state) of tissue, the stratum corneum (SC).
Reviews
There are no reviews yet.